AMLX Stock Discussion

Amylyx Pharmaceuticals, Inc. Description

Amylyx Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company is developing AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid for the treatment of ALS and other neurodegenerative diseases. It is also developing products for Wolfram syndrome and Alzheimer's diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Keywords: Life Sciences Pharmaceutical Alzheimer's Disease Neurodegenerative Diseases Amyotrophic Lateral Sclerosis Nervous System Neurodegenerative Disease Apoptosis